今年，在《临床肿瘤杂志》上发表了一篇名为“Clinical management of metastatic colorectal cancer in the era of precision medicine”的论文，系统阐述了在精准医疗时代，mCRC临床管理的改善情况。
▍滑动查看英文原文:Dr Eng: Interest in neoadjuvant therapy for colon cancer is still up and coming. There are some very intriguing data to suggest that immune checkpoint inhibition or immunotherapy may have a role in early-stage colon cancer. There is some promising activity in early-stage colon cancer as well as early-stage rectal cancer. NEST-1 and -2， were very small studies looking at the role of neoadjuvantl BOT and BAL . This is a small pilot study looking at early-stage colon cancer that suggests there is activity not just in the small number of patients they looked at who were MSI-high， but also in the MSI-stable population which is really intriguing. There was some early data from Myriam Chalabi regarding the NICHE study published many years ago， noticing that giving nivolumab and ipilimumab has activity in early-stage colon cancer. I think that is what really drove this thought process forward. It is very intriguing.
转移性骨肿瘤的患者虽属于晚期癌症，但只要积极治疗，还是能有生存机会！在相同疗效的前提下，相比手*术，微创介入治疗不仅出血少，术后不会出现组织坏死和切口不愈合的风险，降低了术后疼痛、缩短了康复和住院时间，还能降低术后感染等并发症的发生。
